WuXi AppTec Wins Injunction: Pentagon's Military Label Halted for Now

A federal judge just told the Pentagon it misread its own evidence — and the biggest name in contract manufacturing is back in business, at least for now.

Meanwhile Sionna, the cystic fibrosis challenger, lost ninety-two percent of its value in a single session, BridgeBio's Attruby is cruising toward blockbuster land, and three of the biggest names in pharma just sued the state of Illinois. Busy Tuesday. Let's get into it.

Welcome to The Pharma Closeout for Tuesday, August 11th, 2026. I'm Alex Mercer.

And I'm Maya Patel.

Chief Judge James Boasberg granted WuXi AppTec a preliminary injunction — the Defense Department is temporarily barred from enforcing, implementing, or taking any other action pursuant to the 1260H designation. For a research and manufacturing business whose customers had already started walking programs out the door, that's the ruling that stops the bleeding.

The harm language is the tell.

It is. And you have to walk the sequence to feel it. Early June, WuXi lands on the DoD's list of alleged Chinese military companies. That makes it a company of concern under the Biosecure Act, which shuts off US federal procurement and grants tied to its services. WuXi files in late June, gets a hearing on the calendar for July 22 — and every week in between, the commercial damage compounds. This wasn't a company waiting on a label. It was a company watching revenue leave.

Boasberg went further than a scheduling reprieve, though. Per Bloomberg's reporting on the opinion, he found WuXi made a reasonable case the Department acted in an arbitrary and capricious manner — and that the government's claims about the ownership chain, the state assets commission, the defense science administration, the alleged PLA ties, appeared to rest on a misreading. He also said the designation is inflicting harm that later relief cannot repair. The South China Morning Post puts that harm as work suspensions, canceled projects, and programs moved to rival suppliers.

That last one is what sponsors should sit with.

Say more.

Those transfers weren't a memo. They were tech transfer packages, analytical method requalification, comparability work, timeline slippage — real money spent de-risking a designation a federal judge has now called a misreading. And none of that spend comes back with the injunction. The clock reset. The invoice didn't.

Here's my issue with reading this as a win. An injunction is a clock, not a verdict. The comprehensive fight over the classification is still ahead of him, and the Biosecure framework itself rode in on a defense authorization bill — that machinery does not care what one district court said on a Friday. Nothing stops the Department from re-running the designation on a cleaner record.

I'll take the durability point. Where I'd push is on price. A finding of arbitrary and capricious raises the evidentiary bar on any second attempt — the agency now has to build something that survives the same judge who already told them what's wrong with it.

Sure. But raise the bar and you've still left the bar standing. And it lands while lawmakers are separately turning the heat up on US drugmakers doing China licensing deals — so the pressure isn't even routed through this designation anymore.

Then the honest read is narrower than the headline. WuXi won the operational question outright and moved the strategic one exactly zero.

Right — the customer who dual-sourced in June is not un-sourcing in August. Decoupling doesn't get enjoined.

The competitive read: if you paused a WuXi program in June, this ruling hands you back your timeline. It should not hand you back your second supplier. That redundancy just stopped being a hedge and became the cost of operating in this corridor.

And the flip side of that — a company that had a moat and just watched someone fail to cross it.

Vertex. Because Sionna Therapeutics missed, and missed badly. Their NBD1 stabilizer, SION-719, layered on top of Trikafta, produced a mean placebo-adjusted sweat chloride reduction of one point zero millimoles per liter. Sionna's own stated goal going in was ten.

One millimole. That's noise.

The market said the same thing louder.

What nobody's flagging is the design problem underneath the number. Fifteen adults, homozygous for F508del, crossing over between drug and placebo on stable background therapy — and Sionna itself named differential Trikafta exposure between the two periods as a potential confounder. In a crossover that small, the entire value of the design is that each patient serves as their own control. If background exposure isn't stable across periods, the comparison the trial was built on is contaminated. That's not something you fix by enrolling more people.

So the confounder doesn't rescue it — it makes it worse.

It makes it unfalsifiable, which is worse. They can't cleanly claim the drug failed, and they can't cleanly claim the trial failed. Sionna still has the dual combination, SION-451 with SION-2222, and it cleared its exposure targets in healthy volunteers. But BMO called the path forward less clear, and I'd go a step past that — the translational framework that predicted a ten-millimole effect is the asset that broke here, not just the molecule.

Meanwhile Vertex gained six percent Monday, to five hundred twenty-five dollars, without lifting a finger. BMO's line was that the competitive moat around the cystic fibrosis franchise remains deep and wide. That's the whole story of the day for them — the threat removed itself.

Staying with moats — what's happening in ATTR is the same fight with the outcome reversed.

BridgeBio's Attruby did two hundred twenty-two million in second-quarter US sales, six percent ahead of the roughly two hundred ten million consensus, and Jefferies now expects it to clear a billion in annual global sales this year. CEO Neil Kumar is calling this a stabilizer-first market.

He's entitled to say it, but the number that earns it isn't the sales beat. It's from the trial that failed. In CARDIO-TTRansform, fifty-seven percent of patients in each arm were already on a stabilizer at baseline, and another twenty-four percent started one midway through. So four in five patients were stabilized. That wasn't silencer versus standard of care — that was add-on, and Jefferies read the failure as evidence that stacking a silencer on a stabilizer offers no meaningful additive benefit.

Which reframes Alnylam's quarter too. Amvuttra did one point zero one billion — a hundred and six percent growth — and still came in four percent under what analysts wanted. Two companies chasing the same first-line patient, and only one of them just had its combination thesis undercut by someone else's trial.

Both of them have flagged softness in second-line uptake, though. Neither franchise is as clean as the front-line narrative suggests.

One financing to flag before we move — Vaderis Therapeutics closed an oversubscribed Series B, co-led by Goldman Sachs Alternatives and TCGX, and started the global Phase 3 HEROIC study of engasertib in hereditary hemorrhagic telangiectasia.

An oral AKT inhibitor in a rare vascular disease the company says has no approved treatment anywhere in the world — and the release says the money funds them through potential US approval. That's the tell. This syndicate isn't buying a readout. It's buying a regulatory pathway in an indication where nobody has ever built one, which means the trial design is the risk, not the biology.

On the regulatory front — Tenax Therapeutics reported August tenth that oral levosimendan, TNX-103, failed the primary endpoint of the Phase 3 LEVEL trial: six-minute walk distance in pulmonary hypertension due to HFpEF. Three and a half meters over placebo, in a trial powered to detect twenty-five. The one place it moved was a prespecified subgroup with baseline walk under three hundred thirty-three meters — twenty-six point three meters, nominal p of zero point zero one one two.

So the sicker patients moved and nobody else did.

Deeper than that. The post-hoc quartile analysis shows the effect declining as baseline exercise capacity rises — plus thirty-two point four meters in the lowest quartile, minus twenty-seven point three in the highest. A gradient that reverses sign is either a real severity interaction or a ceiling effect in the endpoint itself. Those two readings look identical on the slide and mean opposite things for the enrichment strategy Tenax is now proposing.

Give me the tiebreaker.

The biomarker. A forty-nine percent greater reduction in NT-proBNP versus placebo, with echo improvements alongside it — that's pharmacology doing something real across the whole population. But the quality-of-life secondary was flat. So the drug is changing the heart and not changing the patient, and the subgroup is the company's argument that it can only change patients who are sick enough to have room to improve.

And this molecule has been here before — it failed the Phase 3 Levo-CTS trial in 2017 in cardiac surgery patients with left ventricular dysfunction. Tenax now says it'll request a Type C meeting with FDA, seek parallel EMA advice, and enrich the already-recruiting LEVEL-2 study, with enrollment completion anticipated by the end of 2027. They've previously disclosed that FDA agreed a single Phase 3 hitting p below zero point zero one would support an NDA — a bar the company set out well before this readout.

Which makes it a clean, brutal test. No drug is approved specifically for PH-HFpEF — the approved agents treat the heart failure, not the pulmonary vascular component. If the enriched population reproduces that subgroup, Tenax owns an empty category. If it was a floor artifact, they'll have spent until 2027 proving it.

Also worth noting on the regulatory front — AbbVie, Novartis, and Bristol Myers Squibb each filed separate lawsuits over the past week against Illinois, challenging its 340B contract pharmacy law as unconstitutional. That's now part of an offensive spanning more than fourteen states.

And the filing pattern is the strategy. Separate suits, same constitutional theory, state by state. Nobody here is litigating Illinois — they're building a record for the federal court that eventually has to reconcile fourteen conflicting state statutes. If you have contract pharmacy exposure, the question isn't who wins in Chicago. It's which circuit gets there first, because that's the ruling everybody else has to live under.

Looking ahead — the European Society of Cardiology Congress in Munich at the end of the month is carrying an unusual amount of this slate. Full LEVEL results present August 29th, and the detailed CARDIO-TTRansform data lands at the same meeting.

Which is exactly when BridgeBio says it'll update peak share guidance. They've been targeting thirty to forty percent of the ATTR-cardiomyopathy market — a goal the company equates to more than four billion in peak sales — and that target was set before the silencer failed. Munich decides whether stabilizer-first was a quarter or a structure.

And on WuXi, the injunction buys months, not resolution. Watch whether the Department appeals or quietly rebuilds its evidentiary record — because that choice tells you how much of the Biosecure apparatus actually survives contact with a federal judge.

The one I'll be sitting with tonight is Sionna. A confounded crossover, and a framework that promised ten millimoles and delivered one — that's a company going into a board meeting unable to say whether the science was wrong or the trial was. Enjoy your evening.

And that is your Pharma Closeout for Tuesday, August 11th — Boasberg versus the Pentagon, Vertex's moat holding without a fight, Attruby beating consensus, and levosimendan finding its patients in the wrong half of its own trial. Follow the show on Spotify, Apple Podcasts, or wherever you listen — tomorrow's briefing lands on its own.